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persons, and C,—with surgery to cure the disease itself or its
complications, 18 persons. The average costs were 1060€ per
person and year. The average of yearly costs per person in the
subgroup A were 485€; in the subgroup B it was 1500€, and in
the subgroup C, it was 1,530€. The highest costs per one patient
in the subgroup B were 4265€ and in subgroup C it was 6255€.
The ratio of own patients to all costs was 17.5%, to health care
costs 72.1%, and to social costs 10.4%. Pharmacotherapy
reached 49.7% of the total costs, diagnostic procedures 0.9%,
ambulatory care 19.0%, hospital care 26%, spa care and travel
costs 4.4%. CONCLUSIONS: Crohnxs disease belongs to the
more expensive diseases in the Slovak Republic. There is a sig-
niﬁcant difference in the ratio-structure of costs in comparison
with western countries and the USA. Next pharmacoeconomic
studies in the Slovak Republic should be designed as prospec-
tive, cost of utility studies.
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IS HELICOBACTER PYLORI “TEST AND TREAT” A COST-
EFFECTIVE MANAGEMENT APPROACH FOR PATIENTS WITH
TYPICAL REFLUX SYMPTOMS IN A POPULATION WITH A
HIGH PREVALENCE OF H. PYLORI INFECTION
You JH,Wong PL,Wu JC
The Chinese University of Hong Kong, Shatin, N.T, Hong Kong
OBJECTIVES: Overlap of gastro-oesophageal reﬂux disease
(GERD) and peptic ulcer disease (PUD) in a population with high
prevalence of Helicobacter pylori infections creates clinical
dilemmas in Hong Kong. Testing and eradication of H. pylori
may be a cost-effective alternative for empirical proton-pump
inhibitor (PPI) therapy. To examine the potential clinical and eco-
nomic impact of H. pylori “test and treat” and empirical PPI
therapy for GERD patients with typical reﬂux and high preva-
lence of H. pylori infection. METHODS: A Markov model was
designed to simulate the outcomes of the two treatment strate-
gies over 12 months. The transition probabilities and resource
utilization were derived from literature. Percentage of patients
with PUD treated, total number of quality-adjusted life-years
(QALY’s) gained and total direct medical cost were estimated.
RESULTS: H. pylori “test & treat” was more effective (92.6%
ulcer treated and 0.919 QALYs gained) than empirical PPI
(72.6% ulcer treated and 0.909 QALYs gained). The direct
medical cost per patient in the H. pylori “test and treat” and
empirical PPI arms were USD1901 and USD1770, respectively.
The direct medical cost per patient was sensitive to the variation
of the prevalence of PUD in H. pylori-infected GERD patients.
CONCLUSIONS: H. pylori “test & treat” appeared to be more
effective than empirical PPI therapy, with an incremental cost,
for GERD patients with typical reﬂux in Hong Kong.
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OBJECTIVES: To assess health related quality of life (QOL) and
its predictors among Polish patients with gastroesophageal reﬂux
disease (GERD). METHODS: National survey study was carried
out among 192 Polish general practitioners on out-patients pre-
senting with GERD symptoms. Data on patients’ clinical char-
acteristics, symptoms, treatment and QOL were collected. The
Carlsson’s diagnostic test was used to assess symptoms. A cut-
off score of four or higher was considered positive for GERD.
QOL was measured with SF-36. For the statistical hypothesis
testing the signiﬁcance threshold was set to 0.01. RESULTS:
Data on QOL was collected for 3290 patients, mean age: 
48.9 years (95%CI: 48.4–49.4; males: 47.8% (95%CI:
46.1%–49.5%). Mean health related QOL score was 58.5
(95%CI: 57.9–59.2). Patients with longer history of GERD-asso-
ciated symptoms reported statistically signiﬁcantly lower QOL
(19.1% decrease in QOL for patients with gastroesophageal
reﬂux disease history lasting for ﬁve to 10 years compared to
patients reporting it for less than three months). Adjusting for
case-mix the following symptoms were associated with statisti-
cally signiﬁcantly lower QOL: dysphagia, odynophagia, weight
loss, anaemia, age over 65, hoarseness, rhonchus, fullness, vom-
iting, while heartburn and chest pain or burning sensation and
chronic cough were not. CONCLUSIONS: GERD is associated
with poor QOL, especially for chronic patients. Some symptoms
represent good predicting value for QOL deterioration.
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OBJECTIVES: Gastrointestinal (GI) complications associated
with immunosuppressants are frequently reported by renal trans-
plant recipients. Mycophenolic acid has been associated with an
increased incidence of GI complaints. GI complications may
affect patient Quality of Life (QoL). The purpose of this study
was to psychometrically validate two GI-speciﬁc patient-
reported outcome (PRO) instruments in the renal transplant pop-
ulation. METHODS: The Gastrointestinal Symptom Rating
Scale (GSRS) and Gastrointestinal Quality of Life Index (GIQLI)
were selected for validation. Renal transplant recipients receiv-
ing a calcineurin inhibitor and mycophenolate mofetil were
recruited in a cross-sectional study from 5 clinical centers across
4 countries. Patients completed the GSRS, GIQLI, Psychological
General Well-Being Index (PGWB) and EQ-5D. Statistical analy-
ses employed Cronbach’s alpha, correlations, t-tests and
ANOVA. RESULTS: Of 96 patients recruited (mean age: 47.4 +
12.3 years; male: 56%), 41 (43%) suffered from no, 37 (39%)
mild, 12 (13%) moderate, and 6 (6%) severe GI symptoms.
Internal consistency reliability (Cronbach’s alpha) was >0.7 for
all GIQLI and all but 1 of the GSRS dimensions (abdominal
pain). Correlations between GIQLI and PGWB and EQ-5D were
higher (range: 0.24–0.76) than correlations between GSRS and
PGWB and EQ-5D (range: 0.05–0.54). All GSRS subscales and
the GIQLI total score and 4 subscales signiﬁcantly differentiated
between patients with and without GI complications (p < 0.05),
as did the PGWB total score and EQ-5D. The generic instru-
ments were unable to discriminate between GI severity levels;
conversely, the disease-speciﬁc instruments discriminated to
some extent between GI severity levels. GSRS abdominal pain
subscale discriminated between patients at all levels of severity
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(p < 0.05). GIQLI total score and symptoms subscale discrimi-
nated among most severity levels (p < 0.05). CONCLUSIONS:
The GSRS and GIQLI demonstrated adequate reliability, and
outperformed generic instruments on discriminant validity. Both
instruments can be used to investigate effects on PRO’s related
to GI complications due to immunosuppressant therapies.
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HEALTH-RELATED QUALITY OF LIFE AND PATIENT SELF-
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OBJECTIVES: Irritable bowel syndrome (IBS) is a chronic and
episodic disorder characterized by abdominal pain and altered
bowel habits. Its impact on generic and disease-speciﬁc quality
of life and self-perceived health status is rarely assessed in The
Netherlands. This study assessed the impact of IBS on health-
related quality of life (HRQoL). METHODS: Patients using
mebeverine, identiﬁed at community pharmacies, were adminis-
tered a questionnaire regarding ROME-II-criteria to conﬁrm the
IBS diagnosis, abdominal complaints, use of medical resources,
abdominal pain and discomfort (IGA-P VAS with 0 = no pain
and 1 = very severe pain), patient self-perceived health status
(VAS with 0 = worst imaginable health state i.e. death and 1 =
best possible health state, and SF-6D), generic HRQoL (SF-36)
and IBS-speciﬁc HRQol (IBSQoL). SF-36 outcomes were com-
pared to a random sample of the Dutch population and other
Dutch patients suffering from chronic diseases. The association
between HRQol and severity of disease (IGA-P) was assessed.
RESULTS: A total of 212 completed questionnaires were
received. A total of 169 patients met the ROME-II-criteria for
diagnosis of IBS. Of those, 18% suffered from IBS with diarrhea
predominance, 19% from IBS with constipation predominance
and 51% reported an alternating stool pattern. Severe abdomi-
nal pain (IGA-P >60mm on a 100mm VAS) was reported by
65%. Sufﬁcient differences between the IBS-population and the
Dutch population were measured for all dimensions of the SF-
36. SF-36 and IBSQoL outcomes were associated with disease
severity. Patients regarded their health state as low: 0.62 (0.2)
on a VAS and 0.66 (0.1) using the SF-6D algorithm. CONCLU-
SIONS: IBS has a signiﬁcant impact on all dimensions of HRQol.
Our ﬁndings are consistent with other studies. There is an unmet
medical need in patients suffering from IBS in The Netherlands.
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OBJECTIVES: Primary objective of the study was to determine
the effect of tegaserod six mg b.i.d. on quality of life (QoL) of
women with IBS-C (deﬁned by Rome II criteria). The secondary
objective was to determine the efﬁcacy of tegaserod in this pop-
ulation. METHODS: This was a prospective open-label, multi-
center study in South Africa with gastroenterologist, surgeon and
gynaecologist enrollers. The study comprised a two-week treat-
ment-free baseline period (rescue medication permitted) followed
by a four-week treatment period (rescue medication permitted
for patients not experiencing adequate relief with tegaserod). The
IBS-QoL questionnaire, a validated instrument that assesses the
impact of IBS and treatment of the condition, was completed at
study entry, after the baseline period and at study end. It con-
sists of seven domains: dysphoria, interference with activity,
body image, health worry, food avoidance, social reaction and
sexual relationship. Patients also kept a diary and recorded IBS
symptoms daily and overall symptom relief weekly. RESULTS:
In total, 242 patients from 36 centers were recruited; 210 com-
pleted and were included in the QoL and efﬁcacy analyses. Most
patients were Caucasian (78.1%) and the mean age was 38 (±11)
years. Statistically signiﬁcant improvements after four weeks of
tegaserod treatment were observed for overall QoL (19.6%
improvement from baseline) and for all IBS-QoL domains (both
p < 0.001 vs baseline). Overall, symptom relief was reported by
68.7% of patients at Week four (95% CI: 62.0–75.4%). Statis-
tically signiﬁcant improvements were reported for the number of
bowel movements, stool form, straining, sense of incomplete
evacuation, abdominal pain and bloating (all p £ 0.001).
Symptom improvements were observed early (Week one of treat-
ment) and sustained throughout the study. 58.1% of patients
(95% CI 51.4–64.8%) responded to treatment and concurrently
experienced overall QoL improvement. CONCLUSIONS:
Tegaserod six mg b.i.d. signiﬁcantly improves QoL and is efﬁ-
cacious in women with IBS-C.
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COST-EFFECTIVENESS EVALUATION FOR A NEW
DIAGNOSTIC TEST CONSIDERING ALSO COSTS FOR FALSE
NEGATIVE AND FALSE POSITIVE DIAGNOSES AT VARIOUS
PREVALENCE RATES
Mueller E, Schwander B, Bergemann R
Analytica International, Loerrach, Germany
OBJECTIVES: To evaluate the cost-effectiveness of a diagnostic
technique when no gold standard is available. METHODS:
Capsule endoscopy (CE) is a technique for intraluminal imaging
of the entire small bowel. Sensitivity and speciﬁcity for CE, push
enteroscopy (PE) and other procedures performed prior to diag-
nosis were evaluated from seven controlled clinical trials (n =
184). To evaluate the cost-effectiveness of CE in diagnosing
obscure gastrointestinal bleeding (OGIB) a microsimulation
model was developed. Procedure cost, costs of diagnostic failure
and incremental cost-effectiveness ratios dependent on disease
prevalence are given. Costs due to false negative diagnosis were
examined in cycles with a prevalence range from 10% to 90%.
One way as well as probabilistic sensitivity analysis was per-
formed. Cost data reﬂect the Swiss healthcare payer perspective.
RESULTS: Sensitivity for CE was 89–99% and 27–60% for PE.
Speciﬁcity was 90–99% and 50–70% respectively. Mean future-
costs reach from 7.664€ for cycle 1 to 3.129€ for cycle nine. With
a prevalence >10% CE was the dominant strategy. For a preva-
lence of 50% cost savings are 2240€. CONCLUSIONS: The
model proved to be helpful in the evaluation of CE where gold
standard data were not available. From a health-economic per-
spective the use of CE can be recommended in the work-up of
patients with OGIB. Based on the results of the described method
Switzerland approved reimbursement for CE in patients with
OGIB after negative upper and lower endoscopy.
